## DAFTAR PUSTAKA


1. (KDIGO) KDIGO. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int*. 2013;3:1–150. doi:10.3182/20140824-6-za-1003.01333

2. Bottaro, Larsen B. Disorders Involving Calcium, Phosphorus, and Magnesium. *Prim Care*. 2008;23(1):1–7.

3. Fourtounas C. Phosphorus metabolism in chronic kidney disease. *Hippokratia*. 2011;15(SUPPL. 1):50–52.

4. Vervloet M. Renal and extrarenal effects of fibroblast growth factor 23. *Nat Rev Nephrol*. 2019;15(2):109–120. doi:10.1038/s41581-018-0087-2

5. Scialla JJ, Xie H, Rahman M, et al. Fibroblast growth factor-23 and cardiovascular events in CKD. *J Am Soc Nephrol*. 2014;25(2):349–360. doi:10.1681/ASN.2013050465

6. Shibata K, Fujita S ichi, Morita H, et al. Association between Circulating Fibroblast Growth Factor 23, α-Klotho, and the Left Ventricular Ejection Fraction and Left Ventricular Mass in Cardiology Inpatients. *PLoS One*. 2013;8(9):1–11. doi:10.1371/journal.pone.0073184

7. Sharma S, Hanudel MR, Ix JH, Salusky IB, Ganz T, Nguyen KL. Elevated Fibroblast Growth Factor 23 Levels Are Associated With Greater Diastolic Dysfunction in ESRD. *Kidney Int Reports*. 2019;4(12):1748–1751. doi:10.1016/j.ekir.2019.07.022

8. Seeherunvong W, Abitbol CL, Chandar J, Rusconi P, Zilleruelo GE, Freundlich M. Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis. *Pediatr Nephrol*. 2012;27(11):2129–2136. doi:10.1007/s00467-012-2224-7

9. Tanaka S, Fujita SI, Kizawa S, Morita H, Ishizaka N. Association between FGF23, α-Klotho, and cardiac abnormalities among patients with various chronic kidney disease stages. *PLoS One*. 2016;11(7):1–17. doi:10.1371/journal.pone.0156860

10. Mitsnefes MM, Betoko A, Schneider MF, et al. FGF23 and left ventricular hypertrophy in children with CKD. *Clin J Am Soc Nephrol*. 2018;13(1):45–52. doi:10.2215/CJN.02110217

11. Nitta K, Iimuro S, Imai E, et al. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study. *Clin Exp Nephrol*. 2019;23(1):85–98. doi:10.1007/s10157-018-1605-z

12. Rocco M V., Berns JS. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. *Am J Kidney Dis.* 2012;60(5):850–886. doi:10.1053/j.ajkd.2012.07.005

13. Crews DC, Bello AK, Saadi G, et al. Burden, access, and disparities in kidney disease. *Turkish J Nephrol*. 2019;28(1):1–7. doi:10.5152/turkjnephrol.2019.220119

14. Suwitra K. Penyakit Ginjal Kronik. In: Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setyohadi B, Syam AF, ed. *Buku Ajar Ilmu Penyakit Dalam FK-UI*. VI. Interna Publishing; 2015:348–357.

15. Indonesian P, Registry R, Course H. 10 th Report Of Indonesian Renal Registry 2017 10 th Report Of Indonesian Renal Registry 2017. Published online 2014:1–46.

16. Russo D, Battaglia Y. Clinical Significance of FGF-23 in Patients with CKD. *Int J Nephrol*. 2011;2011:1–5. doi:10.4061/2011/364890

17. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. *J Am Soc Nephrol*. 2005;16(7):2205–2215. doi:10.1681/ASN.2005010052

18. Czaya B, Faul C. The role of fibroblast growth factor 23 in inflammation and anemia. *Int J Mol Sci*. 2019;20(17). doi:10.3390/ijms20174195

19. Kehat I, Molkentin JD. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. *Circulation*. 2010;122(25):2727–2735. doi:10.1161/CIRCULATIONAHA.110.942268

20. Lorell BH, Carabello B a. Clinical Cardiology : New Frontiers Left Ventricular Hypertrophy. *J Am Coll Cardiol*. 2000;60(6):470–479.

21. Kannel WB, Cobb J. Left ventricular hypertrophy and mortality - results from the framingham study. *Cardiol*. 1992;81(4–5):291–298.

doi:10.1159/000175819

22. Kempf T, Wollert KC. Nitric oxide and the enigma of cardiac hypertrophy. *BioEssays*. 2004;26(6):608–615. doi:10.1002/bies.20049

23. Opie L. Mechanism of Caridiac Contraction and Relaxation. In: Libby P, RO B, DL M, DP Z, ed. *Braunwald's Heart Disease*. 8 ed. Saunders Company; 2008:527–559.

24. Solomon SD, Wu J, Galam L. Echocardiography. Published online 2016.

25. Houghton AR. *Making Sense of Echocardiography: A hands-on guide*. 2nd ed. (Press C, ed.).; 2014.

26. St. John Sutton M, Morrison AR, Sinusas AJ, Ferrari VA. Cardiac Imaging in Heart Failure. In: *Heart Failure: a Companion to Braunwald's Heart Disease (Fourth Edition)*. 4th ed. Elsevier; 2020:418-448.e5. doi:10.1016/B978-0-323-60987-6.00032-6

27. Faul C, Keane MG, Wolf M, et al. FGF23 induces left ventricular hypertrophy. 2011;121(11):4393–4408. doi:10.1172/JCI46122.ease

28. Liu QF, Yu LX, Feng JH, Sun Q, Li SS, Ye JM. The prognostic role of Klotho in patients with chronic kidney disease: A Systematic Review and Meta-analysis. *Dis Markers*. 2019;2019. doi:10.1155/2019/6468729

29. Pavik I, Jaeger P, Ebner L, et al. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: A sequence suggested from a cross-sectional

study. *Nephrol Dial Transplant*. 2013;28(2):352–359. doi:10.1093/ndt/gfs460

30. Molkentin JD. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. *Cardiovasc Res*. 2004;63(3):467–475. doi:10.1016/j.cardiores.2004.01.021

31. Vega RB, Bassel-Duby R, Olson EN. Control of cardiac growth and function by calcineurin signaling. *J Biol Chem*. 2003;278(39):36981–36984. doi:10.1074/jbc.R300023200

32. Leifheit-Nestler M, Haffner D. Paracrine effects of FGF23 on the heart. *Front Endocrinol (Lausanne)*. 2018;9(MAY). doi:10.3389/fendo.2018.00278

33. Haynes R, Wheeler DC, Herrington WG, Landray MJ, Baigent C. Cardiovascular Aspects of Kidney Disease. In: Yu ASL, Chertow GM, Luyckx VA, Marsden PA, Skorecki K, Taal MW, ed. *Brenner & Rector's The Kidney*. Vol 2. 11th ed. Elsevier; 2020.

34. Malík J, Danzig V, Bednářová V, Hrušková Z. Echocardiography in patients with chronic kidney diseases. *Cor Vasa*. 2018;60(3):e287–e295. doi:10.1016/j.crvasa.2017.07.008

35. Dohi K. Echocardiographic assessment of cardiac structure and function in chronic renal disease. *J Echocardiogr*. 2019;17(3):115–122. doi:10.1007/s12574-019-00436-x

36. Mavrakanas TA, Khattak A, Singh K, Charytan DM. Echocardiographic parameters and renal outcomes in patients with preserved renal function, and mild- moderate CKD. *BMC Nephrol*. 2018;19(1):1–9. doi:10.1186/s12882-018-0975-5

37. Nardi E, Mulè G, Nardi C, et al. Is echocardiography mandatory for patients with chronic kidney disease? *Intern Emerg Med*. 2019;14(6):923–929. doi:10.1007/s11739-019-02028-0

38. Canziani MEF, Tomiyama C, Higa A, Draibe SA, Carvalho AB. Fibroblast growth factor 23 in chronic kidney disease: Bridging the gap between bone mineral metabolism and Left Ventricular Hypertrophy. *Blood Purif*. 2011;31(1–3):26–32. doi:10.1159/000321368

39. Jovanovich A, Ix JH, Gottdiener J, et al. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. *Atherosclerosis*. 2013;231(1):114–119. doi:10.1016/j.atherosclerosis.2013.09.002

40. Cosyns B, Edvardsen T, Hristova K, Kim HK. Left Ventricle: Systolic Function. In: Lancellotti P, Zamorano JL, Habib G, Badano L, ed. *The EACVI Textbook of Echocardiography*. 2nd ed. Oxford University Press; 2017:131–145.

41. Zhang PF, Zhang Y, Ho SY. Left Ventricle: Morphology and Geometry. In: Lancellotti P, Zamorano JL, Habib G, Badano L, ed. *The EACVI Textbook*

*of Echocardiography*. 2nd ed. Oxford University Press; 2017:123–125.

42. Smiseth otto A, Galderisi M, Oh JK. Left Ventricle: Diastolic Function. In: Lancellotti P, Zamorano JL, Habib G, Badano L, ed. *The EACVI Textbook of Echocardiography*. 2nd ed. Oxford University Press; 2017:147–159.

43. Sinha MD, Turner C, Booth CJ, et al. Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease. *Pediatr Nephrol*. 2015;30(10):1843–1852. doi:10.1007/s00467-015-3125-3

44. Okamoto Y, Fujita S ichi, Morita H, et al. Association between circulating FGF23, α-Klotho, and left ventricular diastolic dysfunction among patients with preserved ejection fraction. *Heart Vessels*. 2016;31(1):66–73. doi:10.1007/s00380-014-0581-9

45. Hosseini MM, Sadat Zahed N, Kazempour M, sadeghi R, Dadras SM, Tabiban S. Assessment of Fibroblast Growth Factor-23 ( Fgf23) as Risk Factor for Diastolic Dysfunction in Hemodialysis Patients. *J Nephrol Ren Dis*. 2017;01(02):1–5. doi:10.4172/2576-3962.1000107

46. Kattel S, Memon S, Saito K, Narula J, Saito Y. An effect of left ventricular hypertrophy on mild-to-moderate left ventricular diastolic dysfunction. *Hell J Cardiol*. 2016;57(2):92–98. doi:10.1016/j.hjc.2016.03.004